Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UHX
|
|||
| Former ID |
DIB005256
|
|||
| Drug Name |
9-AMINOCAMPTOTHECIN
|
|||
| Synonyms |
IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acquired immune deficiency syndrome [ICD-11: 1C62.3; ICD-9: 42] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H17N3O4
|
|||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O
|
|||
| InChI |
1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
|
|||
| InChIKey |
FUXVKZWTXQUGMW-FQEVSTJZSA-N
|
|||
| CAS Number |
CAS 91421-43-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
483848, 600881, 8195177, 11408968, 12014702, 14876953, 14876954, 26725257, 43128571, 50028358, 57318699, 77695393, 87560557, 96023346, 99373552, 99432308, 103073229, 103082936, 103170467, 103910998, 103922005, 104352855, 117586313, 119525751, 124796287, 124953919, 127347071, 127903358, 135030378, 137138142, 142371086, 152036014, 152227690, 160809182, 162179182, 162937855, 163374696, 164758081, 170559265, 172860100, 174531450, 178115205, 179151428, 184538696, 188900245, 198973567, 223445740, 223603491, 225031198, 226414396
|
|||
| ChEBI ID |
CHEBI:80755
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00001427) A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin. U.S. National Institutes of Health. | |||
| REF 2 | Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.